18F-FDG PET in the management of endometrial cancer

Angel Chao, Ting Chang Chang, Koon Kwan Ng, Swei Hsueh, Huei Jean Huang, Hung Hsueh Chou, Chien Sheng Tsai, Tzu Chen Yen, Tzu I. Wu, Chyong Huey Lai

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: Few studies have investigated the clinical impact of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in endometrial cancer. We aimed to assess the value of integrating FDG-PET into the management of endometrial cancer in comparison with conventional imaging alone. Methods: All patients with histologically confirmed primary advanced (stage III/IV) or suspicious/documented recurrent endometrial cancer, with poor prognostic features (serum CA-125 >35 U/ml or unfavourable cell types), or surveillance after salvage therapy were eligible. Before FDG-PET scanning, each patient had received magnetic resonance imaging and/or computed tomography (MRI-CT). The receiver operating characteristic curve method with calculation of the area under the curve (AUC) was used to compare the diagnostic efficacy. Clinical impacts were determined on a scan basis. Results: Forty-nine eligible patients were accrued and 60 studies were performed (27 primary staging, 33 post-therapy surveillance or restaging on relapse). The clinical impact was positive in 29 (48.3%) of the 60 scans. Mean standardised uptake values (SUVs) of true-positive lesions were 13.2 (range 5.7-37.4) for central pelvic lesions and 11.1 (range 1.5-37.4) for metastases. The sensitivity of FDG-PET alone (P

Original languageEnglish
Pages (from-to)36-44
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 2006
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Endometrial Neoplasms
Positron-Emission Tomography
Salvage Therapy
ROC Curve
Area Under Curve
Tomography
Magnetic Resonance Imaging
Neoplasm Metastasis
Recurrence
Serum
Therapeutics

Keywords

  • F-FDG PET
  • Endometrial cancer
  • Primary staging
  • Recurrence
  • Salvage therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Chao, A., Chang, T. C., Ng, K. K., Hsueh, S., Huang, H. J., Chou, H. H., ... Lai, C. H. (2006). 18F-FDG PET in the management of endometrial cancer. European Journal of Nuclear Medicine and Molecular Imaging, 33(1), 36-44. https://doi.org/10.1007/s00259-005-1876-y

18F-FDG PET in the management of endometrial cancer. / Chao, Angel; Chang, Ting Chang; Ng, Koon Kwan; Hsueh, Swei; Huang, Huei Jean; Chou, Hung Hsueh; Tsai, Chien Sheng; Yen, Tzu Chen; Wu, Tzu I.; Lai, Chyong Huey.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 33, No. 1, 01.2006, p. 36-44.

Research output: Contribution to journalArticle

Chao, A, Chang, TC, Ng, KK, Hsueh, S, Huang, HJ, Chou, HH, Tsai, CS, Yen, TC, Wu, TI & Lai, CH 2006, ' 18F-FDG PET in the management of endometrial cancer', European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 1, pp. 36-44. https://doi.org/10.1007/s00259-005-1876-y
Chao, Angel ; Chang, Ting Chang ; Ng, Koon Kwan ; Hsueh, Swei ; Huang, Huei Jean ; Chou, Hung Hsueh ; Tsai, Chien Sheng ; Yen, Tzu Chen ; Wu, Tzu I. ; Lai, Chyong Huey. / 18F-FDG PET in the management of endometrial cancer. In: European Journal of Nuclear Medicine and Molecular Imaging. 2006 ; Vol. 33, No. 1. pp. 36-44.
@article{41e0b65ff0184988bda5727ac0cbe767,
title = "18F-FDG PET in the management of endometrial cancer",
abstract = "Purpose: Few studies have investigated the clinical impact of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in endometrial cancer. We aimed to assess the value of integrating FDG-PET into the management of endometrial cancer in comparison with conventional imaging alone. Methods: All patients with histologically confirmed primary advanced (stage III/IV) or suspicious/documented recurrent endometrial cancer, with poor prognostic features (serum CA-125 >35 U/ml or unfavourable cell types), or surveillance after salvage therapy were eligible. Before FDG-PET scanning, each patient had received magnetic resonance imaging and/or computed tomography (MRI-CT). The receiver operating characteristic curve method with calculation of the area under the curve (AUC) was used to compare the diagnostic efficacy. Clinical impacts were determined on a scan basis. Results: Forty-nine eligible patients were accrued and 60 studies were performed (27 primary staging, 33 post-therapy surveillance or restaging on relapse). The clinical impact was positive in 29 (48.3{\%}) of the 60 scans. Mean standardised uptake values (SUVs) of true-positive lesions were 13.2 (range 5.7-37.4) for central pelvic lesions and 11.1 (range 1.5-37.4) for metastases. The sensitivity of FDG-PET alone (P",
keywords = "F-FDG PET, Endometrial cancer, Primary staging, Recurrence, Salvage therapy",
author = "Angel Chao and Chang, {Ting Chang} and Ng, {Koon Kwan} and Swei Hsueh and Huang, {Huei Jean} and Chou, {Hung Hsueh} and Tsai, {Chien Sheng} and Yen, {Tzu Chen} and Wu, {Tzu I.} and Lai, {Chyong Huey}",
year = "2006",
month = "1",
doi = "10.1007/s00259-005-1876-y",
language = "English",
volume = "33",
pages = "36--44",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - 18F-FDG PET in the management of endometrial cancer

AU - Chao, Angel

AU - Chang, Ting Chang

AU - Ng, Koon Kwan

AU - Hsueh, Swei

AU - Huang, Huei Jean

AU - Chou, Hung Hsueh

AU - Tsai, Chien Sheng

AU - Yen, Tzu Chen

AU - Wu, Tzu I.

AU - Lai, Chyong Huey

PY - 2006/1

Y1 - 2006/1

N2 - Purpose: Few studies have investigated the clinical impact of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in endometrial cancer. We aimed to assess the value of integrating FDG-PET into the management of endometrial cancer in comparison with conventional imaging alone. Methods: All patients with histologically confirmed primary advanced (stage III/IV) or suspicious/documented recurrent endometrial cancer, with poor prognostic features (serum CA-125 >35 U/ml or unfavourable cell types), or surveillance after salvage therapy were eligible. Before FDG-PET scanning, each patient had received magnetic resonance imaging and/or computed tomography (MRI-CT). The receiver operating characteristic curve method with calculation of the area under the curve (AUC) was used to compare the diagnostic efficacy. Clinical impacts were determined on a scan basis. Results: Forty-nine eligible patients were accrued and 60 studies were performed (27 primary staging, 33 post-therapy surveillance or restaging on relapse). The clinical impact was positive in 29 (48.3%) of the 60 scans. Mean standardised uptake values (SUVs) of true-positive lesions were 13.2 (range 5.7-37.4) for central pelvic lesions and 11.1 (range 1.5-37.4) for metastases. The sensitivity of FDG-PET alone (P

AB - Purpose: Few studies have investigated the clinical impact of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in endometrial cancer. We aimed to assess the value of integrating FDG-PET into the management of endometrial cancer in comparison with conventional imaging alone. Methods: All patients with histologically confirmed primary advanced (stage III/IV) or suspicious/documented recurrent endometrial cancer, with poor prognostic features (serum CA-125 >35 U/ml or unfavourable cell types), or surveillance after salvage therapy were eligible. Before FDG-PET scanning, each patient had received magnetic resonance imaging and/or computed tomography (MRI-CT). The receiver operating characteristic curve method with calculation of the area under the curve (AUC) was used to compare the diagnostic efficacy. Clinical impacts were determined on a scan basis. Results: Forty-nine eligible patients were accrued and 60 studies were performed (27 primary staging, 33 post-therapy surveillance or restaging on relapse). The clinical impact was positive in 29 (48.3%) of the 60 scans. Mean standardised uptake values (SUVs) of true-positive lesions were 13.2 (range 5.7-37.4) for central pelvic lesions and 11.1 (range 1.5-37.4) for metastases. The sensitivity of FDG-PET alone (P

KW - F-FDG PET

KW - Endometrial cancer

KW - Primary staging

KW - Recurrence

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=28944452019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944452019&partnerID=8YFLogxK

U2 - 10.1007/s00259-005-1876-y

DO - 10.1007/s00259-005-1876-y

M3 - Article

VL - 33

SP - 36

EP - 44

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 1

ER -